Mostrar el registro sencillo del ítem

dc.contributor.authorCason, Lisiane Turattipt_BR
dc.contributor.authorSprinz, Eduardopt_BR
dc.contributor.authorLazzaretti, Rosmeri Kuhmmerpt_BR
dc.contributor.authorKuhmmer, Reginapt_BR
dc.contributor.authorAgnes, Grasielapt_BR
dc.contributor.authorSilveira, Jussara Mariapt_BR
dc.contributor.authorBasso, Rossana Patriciapt_BR
dc.contributor.authorPinheiro, Cezar Arthur Tavarespt_BR
dc.contributor.authorSilveira, Mariângela Freitas dapt_BR
dc.contributor.authorAlmeida, Silvana dept_BR
dc.contributor.authorRibeiro, Jorge Pintopt_BR
dc.contributor.authorMattevi, Vanessa Sunept_BR
dc.date.accessioned2015-03-04T01:57:52Zpt_BR
dc.date.issued2012pt_BR
dc.identifier.issn0889-2229pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/111605pt_BR
dc.description.abstractHighly active antiretroviral therapy (HAART) has increased the survival of HIV-infected patients. However, adverse effects play a major role in adherence to HAART. Some protease inhibitors (mainly atazanavir and indinavir) act as inhibitors of uridine diphosphate-glucuronosyltransferase (UGT1A1), the enzyme responsible for hepatic conjugation of bilirubin. Variations in the promoter region of the UGT1A1 gene (UGT1A1*28, rs8175347) can influence bilirubin plasma levels, modulating the susceptibility to hyperbilirubinemia. Aiming to analyze the association between UGT1A1*28 allele and hyperbilirubinemia in individuals exposed to HAART, we evaluated 375 HIV-positive individuals on antiretroviral therapy. Individuals carrying the UGT1A1*28 allele had a higher risk of developing severe hyperbilirubinemia [prevalence ratio (PR) = 2.43, 95% confidence interval (CI) 1.08–5.45, p = 0.032] as well as atazanavir users (PR = 7.72, 95% CI = 3.14–18.98, p < 0.001). This is the first description of such an association in Brazilian HIV patients, which shows that in African-American and Euroamerican HAART users, the UGT1A1*28 allele also predisposes to severe hyperbilirubinemia, especially in those exposed to atazanavir.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofAIDS research and human retroviruses. New York. Vol. 28, no. 9 (Sept. 2012), p. 1015-1018pt_BR
dc.rightsOpen Accessen
dc.subjectHiperbilirrubinemiapt_BR
dc.subjectHIVpt_BR
dc.subjectTerapia antirretroviral de alta atividadept_BR
dc.subjectAlelospt_BR
dc.titleShort communication : UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in Southern Brazilpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000865254pt_BR
dc.type.originEstrangeiropt_BR


Ficheros en el ítem

Thumbnail
   

Este ítem está licenciado en la Creative Commons License

Mostrar el registro sencillo del ítem